Pharmaceutical Manufacturing

Pharmaceutical Manufacturing
Share

Pharmaceutical Manufacturing

 •  September 15

According to last year’s “State of the Industry: U.S. Packaging Machinery Report” by PMMI, the pharmaceutical sector is forecasted to have the fastest growth at a CAGR of 2.8 percent through 2020. On a global scale, the demand for pharmaceutical packaging products is expected to increase 6.5 percent annually to over $100 billion by 2019. Each year...

Pharmaceutical Manufacturing

 •  September 13

With key product patent expirations, increased competition from generics and a push for price controls, pharmaceutical companies are under pressure to keep operational budgets to a minimum. A cost-effective manufacturing and supply chain can therefore give pharmaceutical companies a competitive advantage. However, pharmaceutical production lines...

Pharmaceutical Manufacturing

 •  September 7

As pharmaceutical industry trends and demands change, packaging equipment suppliers are rising to the challenge. Today’s suppliers are no longer simply manufacturing equipment - they are involved in the details of the production process. Pharmaceutical Manufacturing asked top suppliers of pharmaceutical packaging systems what needs are being...

Pharmaceutical Manufacturing

 •  September 5

Merck is considering selling its consumer healthcare business, the German pharma company said on Tuesday. While the business unit brings in annual sales of $1 billion, the company says it needs further funds to continue its research into prescription drugs to remain competitive. The company is in the early stages of a strategic review and will be...

As first announced in May 2017, Thermo Fisher Scientific has completed its acquisition of CDMO Patheon N.V. for about $7.2 billion. Today's close follows the expiration of Thermo Fisher's initial tender offer for Patheon at $35.00 per share in cash. "We're pleased to complete our acquisition of Patheon and look forward to the significant value this...

The U.S. Food and Drug Administration approved the first gene therapy available in the United States, offering a new approach to the treatment of cancer and other life-threatening diseases. It approved Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). “We’re entering a new...

Who doesn’t love a deadline extension — especially when it comes to paying taxes or meeting new FDA regulations? Some people and companies always adhere to deadlines, making the necessary preparations so they can move on to the next order of business. Others, like me, wait until the last minute, stress the entire time about the looming deadline,...

Gilead Sciences announced it will acquire Kite Pharma for $180 per share in cash. The transaction, which values Kite at about $11.9 billion, was approved by both Boards of Directors and is expected to close in the fourth quarter of this year. Kite is a leader in the field of cell therapy, and it has developed engineered cell therapies that express...

The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) will start sharing non-public and commercially confidential information, including trade secret information, according to RAPS. Back in March, the agencies announced their agreement to recognize each other's pharma manufacturing inspections, with the goal of reducing...

The U.S. FDA has warned Chinese manufacturer Foshan Flying Medical Products for testing, training and validation issues at its Guangdong, China plant. The inspection took place from February 20-23, 2017. According to the FDA letter, dated August 1, the facility: • lacks an adequate quality control unit • released finished drug products without...